Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile.

Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, Chowdhury FZ, Maswabi K, Ajibola G, Moyo S, Mohammed T, Ncube T, Makhema J, Jean-Philippe P, Yu XG, Powis KM, Lockman S, Kuritzkes DR, Shapiro R, Lichterfeld M.

Sci Transl Med. 2019 Nov 27;11(520). pii: eaax7350. doi: 10.1126/scitranslmed.aax7350.

PMID:
31776292
2.

Pharmacological modulation of the Wnt/β-catenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4+ T-cells in ART-suppressed SIV-infected macaques.

Mavigner M, Zanoni M, Tharp GK, Habib J, Mattingly CR, Lichterfeld M, Nega MT, Vanderford TH, Bosinger SE, Chahroudi A.

J Virol. 2019 Oct 16. pii: JVI.01094-19. doi: 10.1128/JVI.01094-19. [Epub ahead of print]

3.

HIV-1 DNA sequence diversity and evolution during acute subtype C infection.

Lee GQ, Reddy K, Einkauf KB, Gounder K, Chevalier JM, Dong KL, Walker BD, Yu XG, Ndung'u T, Lichterfeld M.

Nat Commun. 2019 Jun 21;10(1):2737. doi: 10.1038/s41467-019-10659-2.

4.

ART reduces T cell activation and immune exhaustion markers in HIV controllers.

Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE; AIDS Clinical Trials Group Study A5308 Team.

Clin Infect Dis. 2019 May 25. pii: ciz442. doi: 10.1093/cid/ciz442. [Epub ahead of print]

PMID:
31131858
5.

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.

AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213.

PMID:
30932955
6.

Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy.

Einkauf KB, Lee GQ, Gao C, Sharaf R, Sun X, Hua S, Chen SM, Jiang C, Lian X, Chowdhury FZ, Rosenberg ES, Chun TW, Li JZ, Yu XG, Lichterfeld M.

J Clin Invest. 2019 Mar 1;129(3):988-998. doi: 10.1172/JCI124291. Epub 2019 Jan 28.

7.

Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers.

Chowdhury FZ, Ouyang Z, Buzon M, Walker BD, Lichterfeld M, Yu XG.

AIDS. 2018 Nov 28;32(18):2669-2677. doi: 10.1097/QAD.0000000000002007.

8.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ.

J Clin Invest. 2018 Aug 31;128(9):4074-4085. doi: 10.1172/JCI120549. Epub 2018 Aug 20.

9.

Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana.

Ibrahim M, Maswabi K, Ajibola G, Moyo S, Hughes MD, Batlang O, Sakoi M, Auletta-Young C, Vaughan L, Lockman S, Jean-Philippe P, Yu X, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RL.

J Int AIDS Soc. 2018 May;21(5):e25111. doi: 10.1002/jia2.25111.

10.

Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells.

Kuo HH, Ahmad R, Lee GQ, Gao C, Chen HR, Ouyang Z, Szucs MJ, Kim D, Tsibris A, Chun TW, Battivelli E, Verdin E, Rosenberg ES, Carr SA, Yu XG, Lichterfeld M.

Immunity. 2018 Jun 19;48(6):1183-1194.e5. doi: 10.1016/j.immuni.2018.04.004. Epub 2018 May 22.

11.

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.

Brinkmann CR, Højen JF, Rasmussen TA, Kjær AS, Olesen R, Denton PW, Østergaard L, Ouyang Z, Lichterfeld M, Yu X, Søgaard OS, Dinarello C, Tolstrup M.

mSphere. 2018 Feb 14;3(1). pii: e00616-17. doi: 10.1128/mSphere.00616-17. eCollection 2018 Jan-Feb.

12.

A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers.

Martin-Gayo E, Cole MB, Kolb KE, Ouyang Z, Cronin J, Kazer SW, Ordovas-Montanes J, Lichterfeld M, Walker BD, Yosef N, Shalek AK, Yu XG.

Genome Biol. 2018 Jan 29;19(1):10. doi: 10.1186/s13059-017-1385-x.

13.

Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW.

PLoS Pathog. 2018 Jan 11;14(1):e1006792. doi: 10.1371/journal.ppat.1006792. eCollection 2018 Jan.

14.

Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.

Clin Infect Dis. 2018 Jun 1;66(12):1910-1917. doi: 10.1093/cid/cix1111.

15.

Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication.

Sun X, Hua S, Chen HR, Ouyang Z, Einkauf K, Tse S, Ard K, Ciaranello A, Yawetz S, Sax P, Rosenberg ES, Lichterfeld M, Yu XG.

Cell Rep. 2017 Dec 19;21(12):3471-3482. doi: 10.1016/j.celrep.2017.11.087.

16.

Recent progress in understanding HIV reservoirs.

Kuo HH, Lichterfeld M.

Curr Opin HIV AIDS. 2018 Mar;13(2):137-142. doi: 10.1097/COH.0000000000000441. Review.

17.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

18.

Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection.

Orlova-Fink N, Chowdhury FZ, Sun X, Harrington S, Rosenberg ES, Yu XG, Lichterfeld M.

AIDS. 2017 Oct 23;31(16):2211-2215. doi: 10.1097/QAD.0000000000001630.

19.

Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells.

Lee GQ, Orlova-Fink N, Einkauf K, Chowdhury FZ, Sun X, Harrington S, Kuo HH, Hua S, Chen HR, Ouyang Z, Reddy K, Dong K, Ndung'u T, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M.

J Clin Invest. 2017 Jun 30;127(7):2689-2696. doi: 10.1172/JCI93289. Epub 2017 Jun 19.

20.

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Vibholm L, Schleimann MH, Højen JF, Benfield T, Offersen R, Rasmussen K, Olesen R, Dige A, Agnholt J, Grau J, Buzon M, Wittig B, Lichterfeld M, Petersen AM, Deng X, Abdel-Mohsen M, Pillai SK, Rutsaert S, Trypsteen W, De Spiegelaere W, Vandekerchove L, Østergaard L, Rasmussen TA, Denton PW, Tolstrup M, Søgaard OS.

Clin Infect Dis. 2017 Jun 15;64(12):1686-1695. doi: 10.1093/cid/cix201.

21.

Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.

Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Schulze Zur Wiesch J, Cubas R, Porichis F, Shalek AK, van Lunzen J, Haddad EK, Walker BD, Kaufmann DE, Lichterfeld M, Yu XG.

JCI Insight. 2017 Jan 26;2(2):e89574. doi: 10.1172/jci.insight.89574.

22.

T memory stem cells in health and disease.

Gattinoni L, Speiser DE, Lichterfeld M, Bonini C.

Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241. Review.

23.

The loss of CCR6+ and CD161+ CD4+ T-cell homeostasis contributes to disease progression in SIV-infected rhesus macaques.

McGary CS, Alvarez X, Harrington S, Cervasi B, Ryan ES, Iriele RI, Paganini S, Harper JL, Easley K, Silvestri G, Ansari AA, Lichterfeld M, Micci L, Paiardini M.

Mucosal Immunol. 2017 Jul;10(4):1082-1096. doi: 10.1038/mi.2016.116. Epub 2017 Jan 4.

24.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, Gonzalez-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, Leal M, Lichterfeld M, Ruiz-Mateos E; ECRIS integrated in the Spanish AIDS Research Network.

Clin Infect Dis. 2017 Mar 1;64(5):621-628. Epub 2016 Dec 16.

25.

HLA-G+ HIV-1-specific CD8+ T cells are associated with HIV-1 immune control.

Viganò S, Negrón JJ, Tse S, Chowdhury FZ, Lichterfeld M, Yu XG.

AIDS. 2017 Jan 14;31(2):207-212. doi: 10.1097/QAD.0000000000001326.

26.

Broad activation of latent HIV-1 in vivo.

Barton K, Hiener B, Winckelmann A, Rasmussen TA, Shao W, Byth K, Lanfear R, Solomon A, McMahon J, Harrington S, Buzon M, Lichterfeld M, Denton PW, Olesen R, Østergaard L, Tolstrup M, Lewin SR, Søgaard OS, Palmer S.

Nat Commun. 2016 Sep 8;7:12731. doi: 10.1038/ncomms12731.

27.

Follicular T helper cells: hotspots for HIV-1 persistence.

Paiardini M, Lichterfeld M.

Nat Med. 2016 Jul 7;22(7):711-2. doi: 10.1038/nm.4138. No abstract available.

PMID:
27387885
28.

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD.

PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.

29.

Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations.

Lee GQ, Lichterfeld M.

Curr Opin HIV AIDS. 2016 Jul;11(4):383-7. doi: 10.1097/COH.0000000000000281. Review.

30.

Correction: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 22;12(3):e1005532. doi: 10.1371/journal.ppat.1005532. eCollection 2016 Mar. No abstract available.

31.

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 3;12(3):e1005472. doi: 10.1371/journal.ppat.1005472. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005532.

32.

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS.

Lancet HIV. 2014 Oct;1(1):e13-21. doi: 10.1016/S2352-3018(14)70014-1. Epub 2014 Sep 15.

PMID:
26423811
33.

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir.

Ouyang Z, Buzon MJ, Zheng L, Sun H, Yu XG, Bosch RJ, Mellors JW, Eron JJ, Gandhi RT, Lichterfeld M.

Open Forum Infect Dis. 2015 Apr 1;2(2):ofv045. doi: 10.1093/ofid/ofv045. eCollection 2015 Apr.

34.

Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.

Sun H, Kim D, Li X, Kiselinova M, Ouyang Z, Vandekerckhove L, Shang H, Rosenberg ES, Yu XG, Lichterfeld M.

J Virol. 2015 Nov;89(22):11284-93. doi: 10.1128/JVI.01595-15. Epub 2015 Sep 2.

35.

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Olesen R, Vigano S, Rasmussen TA, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.

J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15. Epub 2015 Jul 29.

36.

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers.

Martin-Gayo E, Buzon MJ, Ouyang Z, Hickman T, Cronin J, Pimenova D, Walker BD, Lichterfeld M, Yu XG.

PLoS Pathog. 2015 Jun 11;11(6):e1004930. doi: 10.1371/journal.ppat.1004930. eCollection 2015 Jun.

37.

Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties.

Vigano S, Negron J, Ouyang Z, Rosenberg ES, Walker BD, Lichterfeld M, Yu XG.

J Virol. 2015 Aug;89(15):7829-40. doi: 10.1128/JVI.00789-15. Epub 2015 May 20.

38.

Immuno-modulatory strategies for reduction of HIV reservoir cells.

Banks HT, Flores KB, Hu S, Rosenberg E, Buzon M, Yu X, Lichterfeld M.

J Theor Biol. 2015 May 7;372:146-58. doi: 10.1016/j.jtbi.2015.02.006. Epub 2015 Feb 17.

39.

T memory stem cells and HIV: a long-term relationship.

Chahroudi A, Silvestri G, Lichterfeld M.

Curr HIV/AIDS Rep. 2015 Mar;12(1):33-40. doi: 10.1007/s11904-014-0246-4. Review.

40.

Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.

Rokx C, Richman DD, Müller-Trutwin M, Silvestri G, Lunzen J, Khoo S, Lichterfeld M, Altfeld M, Perno CF, Hunt PW, Mallon P, Rockstroh JK, Pozniak AL, Clotet B, Boucher CA.

J Virus Erad. 2015 Jul 1;1(3):211-20.

41.

Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis.

Gaiha GD, McKim KJ, Woods M, Pertel T, Rohrbach J, Barteneva N, Chin CR, Liu D, Soghoian DZ, Cesa K, Wilton S, Waring MT, Chicoine A, Doering T, Wherry EJ, Kaufmann DE, Lichterfeld M, Brass AL, Walker BD.

Immunity. 2014 Dec 18;41(6):1001-12. doi: 10.1016/j.immuni.2014.12.011. Epub 2014 Dec 8.

42.

Studies on quantitative phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curves.

Ho HP, Rathod P, Louis M, Tada CK, Rahaman S, Mark KJ, Leng J, Dana D, Kumar S, Lichterfeld M, Chang EJ.

Rapid Commun Mass Spectrom. 2014 Dec 30;28(24):2681-9. doi: 10.1002/rcm.7063.

43.

Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.

Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD.

PLoS Pathog. 2014 Aug 14;10(8):e1004287. doi: 10.1371/journal.ppat.1004287. eCollection 2014 Aug.

44.

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.

Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M.

J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14. Epub 2014 Jun 25.

45.

A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers.

Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, Chang EJ, Lichterfeld M.

Cell Host Microbe. 2014 Jun 11;15(6):717-728. doi: 10.1016/j.chom.2014.05.011.

46.

CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Jost S, Tomezsko PJ, Rands K, Toth I, Lichterfeld M, Gandhi RT, Altfeld M.

J Virol. 2014 Aug;88(15):8349-54. doi: 10.1128/JVI.00924-14. Epub 2014 May 14.

47.

LILRB2 interaction with HLA class I correlates with control of HIV-1 infection.

Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, Bream JH, Duggal P, Hussain S, Martinson J, Weintrob A, Kirk GD, Fellay J, Buchbinder SP, Goedert JJ, Deeks SG, Pereyra F, Trowsdale J, Lichterfeld M, Telenti A, Walker BD, Allen RL, Carrington M, Yu XG.

PLoS Genet. 2014 Mar 6;10(3):e1004196. doi: 10.1371/journal.pgen.1004196. eCollection 2014 Mar.

48.

Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.

Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study.

PLoS One. 2014 Jan 17;9(1):e85516. doi: 10.1371/journal.pone.0085516. eCollection 2014.

49.

HIV-1 persistence in CD4+ T cells with stem cell-like properties.

Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J, Henrich TJ, Li JZ, Pereyra F, Zurakowski R, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M.

Nat Med. 2014 Feb;20(2):139-42. doi: 10.1038/nm.3445. Epub 2014 Jan 12.

50.

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M.

J Infect Dis. 2014 May 1;209(9):1315-20. doi: 10.1093/infdis/jit628. Epub 2013 Nov 25.

Supplemental Content

Loading ...
Support Center